CO2018010874A2 - Vacuna de virus de zika atenuado vivo - Google Patents

Vacuna de virus de zika atenuado vivo

Info

Publication number
CO2018010874A2
CO2018010874A2 CONC2018/0010874A CO2018010874A CO2018010874A2 CO 2018010874 A2 CO2018010874 A2 CO 2018010874A2 CO 2018010874 A CO2018010874 A CO 2018010874A CO 2018010874 A2 CO2018010874 A2 CO 2018010874A2
Authority
CO
Colombia
Prior art keywords
attenuated
virus
zikv
vaccines
zika
Prior art date
Application number
CONC2018/0010874A
Other languages
English (en)
Inventor
Stephen S Whitehead
Anna P Durbin
Sara E Woodson
Alexander G Pletnev
Konstantin A Tsetsarkin
Original Assignee
Univ Johns Hopkins
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Us Health filed Critical Univ Johns Hopkins
Publication of CO2018010874A2 publication Critical patent/CO2018010874A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se relaciona con virus y vacunas de Zika atenuado, virus y vacunas de Zika quimérico atenuado, y composiciones inmunogénicas multivalentes que comprenden vacunas de Zika y vacunas para otros flavivirus. Los virus de Zika quimérico incluyen una primera secuencia de nucleótido que codifica por lo menos una proteína estructural de un virus Zika (ZIKV), una segunda secuencia de nucleótido que codifica por lo menos una proteína no estructura de un primer flavivirus, y una tercera secuencia de nucleótido de una región (3’) sin trasladar de un segundo flavivirus. Las composiciones inmunogénicas multivalentes comprenden una vacuna de ZIKV atenuado o una vacuna de ZIKV quimérico sin atenuar (o su combinación) junto con uno o más de un primer virus atenuado que es inmunogénico contra el serotipo (1) de dengue, un segundo virus atenuado que es inmunogénico contra el serotipo (2) de dengue, un tercer virus atenuado que es inmunogénico contra el serotipo (3) de dengue, y un cuarto virus atenuado que es inmunogénico contra el serotipo (4) de dengue. La presente divulgación además se relaciona con métodos para inducir respuestas inmunes, así como prevenir o tratar infecciones de ZIKV, y en ciertas modalidades, la prevención combinada con tratamiento de ZIKV y otros flavivirus, por ejemplo, virus de dengue.
CONC2018/0010874A 2016-03-11 2018-10-10 Vacuna de virus de zika atenuado vivo CO2018010874A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307170P 2016-03-11 2016-03-11
PCT/US2017/021989 WO2017156511A1 (en) 2016-03-11 2017-03-11 Live attenuated zika virus vaccine

Publications (1)

Publication Number Publication Date
CO2018010874A2 true CO2018010874A2 (es) 2018-10-22

Family

ID=58428363

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0010874A CO2018010874A2 (es) 2016-03-11 2018-10-10 Vacuna de virus de zika atenuado vivo

Country Status (11)

Country Link
US (1) US20190194260A1 (es)
EP (1) EP3426292A1 (es)
JP (1) JP2019511221A (es)
KR (1) KR20180127397A (es)
CN (1) CN109152828A (es)
AU (1) AU2017230112A1 (es)
BR (1) BR112018068342A2 (es)
CA (1) CA3016697A1 (es)
CO (1) CO2018010874A2 (es)
MX (1) MX2018010958A (es)
WO (1) WO2017156511A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
GB201716307D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric yellow fever zika virus strain
EP3710046A4 (en) 2017-11-10 2021-11-17 The Research Institute at Nationwide Children's Hospital RECOMBINANT VECTORS CODING FOR ZIKA VIRUS PROTEIN SUB-UNITS
BR112021004049A2 (pt) * 2018-09-04 2021-05-25 The Board Of Regents Of The University Of Texas System vacinas vivas atenuadas lançadas por plasmídeo de dna para vírus de rna de fita simples de sentido positivo
CN114302738A (zh) * 2019-06-25 2022-04-08 科达金尼克斯有限公司 减毒登革病毒
US20240131197A1 (en) * 2021-02-26 2024-04-25 Duke University Compositions For and Methods of Improving Gene Therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3815601A (en) 2000-02-10 2001-08-20 Us Health Full-length infectious cDNA clones of tick borne flavivirus
EP2292802B1 (en) 2001-05-22 2015-01-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
IL162949A0 (en) 2002-01-10 2005-11-20 Us Gov Health & Human Serv Construction of west nile virus and dengue virus chimeras for use in a virus vaccine to prevent disease caused by west nile virus
TR201806655T4 (tr) 2002-05-03 2018-06-21 The Government Of The Secretary Department Of Health And Human Services Dang tipi 4 genomunun 3' translate edilmemiş bölgesinin bir kesitinde bir 30 nükleotit delesyonunu (delta30) içeren bir rden3/4delta 30(me), rden2/4delta30(me) ya da rden1/4delta30(me) rekombinant kimerik dang virüsü olup, burada adı geçen 30 nükleotit delesyonu tl2 stem-loop yapısına karşılık gelir.
CA2894300A1 (en) 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
US7851194B2 (en) 2004-06-14 2010-12-14 The United States Of America As Represented By The Department Of Health And Human Services West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines
HUE029333T2 (en) 2006-08-15 2017-03-28 The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Development of Dengue virus vaccine components
US20100316670A1 (en) 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
WO2012065105A2 (en) * 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines

Also Published As

Publication number Publication date
EP3426292A1 (en) 2019-01-16
US20190194260A1 (en) 2019-06-27
WO2017156511A8 (en) 2018-09-27
AU2017230112A1 (en) 2018-10-04
BR112018068342A2 (pt) 2019-01-15
WO2017156511A1 (en) 2017-09-14
CN109152828A (zh) 2019-01-04
CA3016697A1 (en) 2017-09-14
KR20180127397A (ko) 2018-11-28
JP2019511221A (ja) 2019-04-25
MX2018010958A (es) 2019-02-07

Similar Documents

Publication Publication Date Title
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
MX2018014573A (es) Vacuna contra el virus del zika.
EA201800108A1 (ru) Вакцинные композиции для профилактики абровирусных инфекций
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
AR106026A1 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
AR109538A1 (es) Vacuna contra la gripe porcina
AR101814A1 (es) Partícula de tipo virus flavivirus
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
CO2018010359A2 (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
MX2020004833A (es) Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с